Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,043 mentions
- robotic manipulationmarket824 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology491 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology371 mentions
- agentic AItechnology353 mentions
- vision-language-action modeltechnology350 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Vision-Language Modeltechnology318 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology175 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology169 mentions
- IBMorganization163 mentions
Entity
LYMPHIR
product2 mentionslast seen Nov 4, 2026
Targeted immunotherapy for relapsed or refractory cutaneous T-cell lymphoma, a recombinant fusion protein combining IL-2 receptor binding domain with diphtheria toxin fragments.
Relationships 8
- LYMPHIRapplies tocutaneous T-cell lymphoma treatment99% confidence2 sources
- Citius Oncology, Inc.commercializesLYMPHIR99% confidence2 sources
- U.S. Food and Drug AdministrationapprovesLYMPHIR96% confidence1 source
- U.S. Food and Drug AdministrationapprovesLYMPHIR96% confidence1 source
- Citius Oncology, Inc.developsLYMPHIR95% confidence1 source
- LYMPHIRcomposed ofIL-2 receptor binding domain90% confidence1 source
- Citius Oncology, Inc.developsLYMPHIR90% confidence1 source
- LYMPHIRconforms toOrphan Drug designation80% confidence1 source
Relationship
Citius Oncology, Inc.commercializesLYMPHIR
99% confidence2 supporting mentionsfrom Dec 1, 2025
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGARNov 4, 2026CITIUS ONCOLOGY, INC. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
In December 2025, Citius Oncology launched LYMPHIR
- filingSEC EDGARNov 4, 2026Citius Pharmaceuticals, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
In December 2025, Citius Oncology launched LYMPHIR